Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntenSify: Cobicistat with Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
NCT05494866Phase 1Terminated
- Sponsor
- German Cancer Research Center
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cobicistat in pancreatic ductal adenocarcinoma (PDAC), sponsored by German Cancer Research Center. Started Dec 2022; status: terminated.
02
Drugs
cobicistat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05494866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494866.